FIELD: immunology, biotechnology, in particular antibody modified by gene-engineering methods.
SUBSTANCE: obtained antibody contains two or more V-regions of H-chain and two or more V-regions of L-chain of monoclonal antibody and is capable of signal transduction into cells by formation of cross-linked cell surface molecule (molecules). Modifies antibody is useful as transduction signal agonist and as prophylaxis and/or treatment agent for various diseases, such as cancer, inflammation, hormonal disturbances and blood diseases. Modifies antibody also is useful in inducing of antagonistic action in relates to cells. Also disclosed are method for detection of abovementioned antibody and method for measurement of antibody antagonistic action in relates to cells.
EFFECT: antibodies of low molecular mass having antagonistic action due to cross-linking of cell surface molecule or intracell molecule.
31 cl, 96 dwg, 3 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DEGRADED ANTIBODY AS TPO AGONIST | 2001 |
|
RU2287534C2 |
| METHOD AND SET FOR DETECTING GENE ENCODING MEMBRANE-BOUND PROTEIN, VECTOR (VARIANTS) | 1999 |
|
RU2246538C2 |
| TUMOR-SPECIFIC ANTI-EGFR ANTIBODY AND USE THEREOF | 2016 |
|
RU2730605C2 |
| RECOMBINANT Fab-scFv BASED ON A NEUTRALISING ANTIBODY AGAINST HUMAN BETA-1A INTERFERON AND AN ANTIBODY AGAINST HUMAN ErbB2 RECEPTOR | 2019 |
|
RU2748953C1 |
| MONOMOLECULAR CHIMERIC T-CELL RECEPTOR TO CANCER ANTIGEN CA125 | 2018 |
|
RU2747095C2 |
| COMPOSITIONS AND METHODS FOR MODIFICATION OF SPECIFIED TARGET NUCLEIC ACID SEQUENCE | 2012 |
|
RU2663354C2 |
| CONSTRUCTED HIGH-AFFINITY HUMAN T-CELL RECEPTORS | 2014 |
|
RU2740648C2 |
| ANTI-GLYPICAN 3-ANTIBODY HAVING MODIFIED SUGAR CHAIN | 2005 |
|
RU2451030C2 |
| METHOD OF SECRETORY PROTEIN PRODUCTION | 2012 |
|
RU2588439C2 |
| ANTIBODY AGAINST THE CELL ADHESION MOLECULE L1 OR ITS ANTIGEN-BINDING FRAGMENT AND CHIMERIC ANTIGEN RECEPTOR CONTAINING IT | 2019 |
|
RU2789360C2 |
